INTRODUCTION
Heparan sulphate proteoglycans (HSPGs) are present ubiquitously on the cell surface, extracellular matrix and basement membranes [1, 2] . The HS chains in HSPGs interact with huge numbers of ligands such as growth factors, morphogens, proteases, viral glycoproteins and basement membrane components [3] [4] [5] . These interactions in in itro and in i o systems have been shown to be implicated not only in various cell behaviours such as cell growth, differentiation, adhesion and migration, but also in tissue morphogenesis during development [6] [7] [8] [9] . Furthermore, HS is involved in various patho-physiological phenomena such as inflammation, blood coagulation, tumour cell malignancy and microbial infection [10, 11] . Recent genetic studies on Drosophila, Caenorhabditis elegans, Zebrafish and mice are uncovering these functions of HSPGs [12] .
Not all but most interactions between HS and ligand molecules occur in regions of the HS with specific monosaccharide sequences and sulphation positions [13] . These sequences are generated by complex but strictly regulated modification reacAbbreviations used : CDSNS-heparin, completely desulphated and N-resulphated heparin ; CHO, Chinese-hamster ovary ; ∆Di-NS, 2-deoxy-2-sulphamino-4-O-(4-deoxy-α-L-threo-hex-4-enepyranosyluronic acid)-D-glucose ; ∆Di-(N,2)diS, 2-deoxy-2-sulphamino-4-O-(4-deoxy-2-O-sulpho-α-Lthreo-hex-4-enepyranosyluronic acid)-D-glucose ; ∆Di-(N,6)diS, 2-deoxy-2-sulphamino-4-O-(4-deoxy-α-L-threo-hex-4-enepyranosyluronic acid)-6-Osulpho-D-glucose ; ∆Di-(N,6,2)triS, 2-deoxy-2-sulphamino-4-O-(4-deoxy-2-O-sulpho-α-L-threo-hex-4-enepyranosyluronic acid)-6-O-sulpho-D-glucose ; ∆Di-OS, 2-acetamide-2-deoxy-4-O-(4-deoxy-α-L-threo-hex-4-enepyranosyluronic acid)-D-glucose ; ∆Di-6S, 2-acetamide-2-deoxy-4-O-(4-deoxy-α-Lthreo-hex-4-enepyranosyluronic acid)-6-O-sulpho-D-glucose ; FISH, fluorescence in situ hybridization ; GAG, glycosaminoglycan ; GlcA, glucuronic acid ; GlcNAc, N-acetylglucosamine ; GlcNSO 3 , N-sulphoglucosamine ; HexA, hexuronic acid ; HS, heparan sulphate ; HS6ST, HS 6-O-sulphotransferase ; HSPG, heparan sulphate proteoglycan ; IdoA, iduronic acid ; NS-heparosan, deacetylated and N-sulphated heparosan ; PAPS, adenosine 3h-phosphate 5h-phosphosulphate ; RT, reverse transcriptase. 1 To whom correspondence should be addressed (e-mail Kimata!amugw.aichi-med-u.ac.jp).
The nucleotide sequences reported in the present study have been submitted to the DDBJ/GenBank2/EMI DataBank with accession nos AB067776 (human HS6ST-2 mRNA) and AB067777 (human HS6ST-2S mRNA).
were different. Dot-blot analysis of the two forms showed that the original form was exclusively expressed in adult and foetal brain tissues, whereas the short form was expressed preferentially in ovary, placenta and foetal kidney, suggesting that the expression of two forms of hHS6ST-2 is strictly regulated to yield tissue-dependent differences in the fine structure of HS. A refined analysis of their reaction products has led us to another finding, that HS6STs could also transfer sulphate to N-sulphoglucosamine residues located at the non-reducing terminal of HS with high affinity.
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tions during the biosynthesis of HS [14] . To clarify the biological function of the sophisticated structure of HSs, it is important to reveal the regulation mechanism of the biosynthesis of HS. At the first step in the biosynthesis of HS, xylose (Xyl) assembles at specific serine residues on the core protein, and after the completion of the linkage structure GlcA-Gal-Gal-Xyl (where GlcA stands for glucuronic acid), transfer of the first Nacetylglucosamine (GlcNAc) residue is followed by the elongation of repeating units composed of GlcA and GlcNAc residues [15] . These precursor HS chains undergo a series of modification reactions [11, 16, 17] : N-deacetylation and N-sulphation of GlcNAc residue, conversion of GlcA into iduronic acid (IdoA), 2-O-sulphation of IdoA residue, 6-O-sulphation of N-sulphoglucosamine (GlcNSO $ ) residue and 3-O-sulphation of GlcNSO $ \ glucosamine residue. The extent to which the modifications proceed and the order in which each modification occurs generate the divergent structures in the HS. In vertebrates, each modification reaction, except for GlcA C-5 epimerase [18, 19] and HS 2-O-sulphotransferase [20] , is catalysed by isoforms that are derived from different but related genes and constitute a gene family ; N-deacetylation and N-sulphation of GlcNAc residue by four HS N-deacetylases and N-sulphotransferases [21] [22] [23] [24] [25] , 6-Osulphation of GlcNSO $ residue by three heparan sulphate 6-O-sulphotransferases (HS6STs) [26, 27] , and 3-O-sulphation of GlcNSO $ \glucosamine residue by at least five HS3-O-STs [28] [29] [30] . However, in invertebrates such as Drosophila and C. elegans, only one HS N-deacetylase and N-sulphotransferase and one HS6ST appear to be involved in the N-sulphation and 6-O-sulphation respectively [31, 32] . The occurrence of multiple isoforms of the enzymes may indicate that the biosynthesis of HS is much more strictly regulated in vertebrates than in invertebrates. We described three isoforms of mouse HS6ST encoded by distinct genes previously. The expression patterns, substrate specificities and catalytic properties of these isoforms were quite different from each other. Drosophila has only one HS6ST that shows intermediate substrate specificity between mouse (m)HS6ST-1 and mHS6ST-2 [32] . We have also suggested that Drosophila HS6ST plays a pivotal role in tracheal development by affecting signal transduction via fibroblast growth factor receptor (breathless). The apparent requirement of Drosophila HS6ST in the tracheogenesis may correspond to the observation in vertebral systems that 6-O-sulphated glucosamine residues as well as 2-Osulphated IdoA residues in HS are unequivocally needed for fibroblast growth factor 2 signalling [33] [34] [35] [36] . The Drosophila system seems to offer valuable information on human diseases, because Drosophila tracheogenesis shares many features with the angiogenesis that is disordered in various human diseases [32] .
We have investigated human isologues of HS6Ts to determine whether or not the properties of the human enzymes are different from those of other animal enzymes and to clarify the relationship between the fine structures of HS and human disease. We described the complete sequence of human HS6ST-1 previously and studied some of the enzyme properties as the first report on HS6ST [26] . Although we were isolating the cDNA of human isologues of HS6T-2, we found two forms generated by alternative splicing. In the present study, we show the occurrence of HS6ST-2 and its alternatively spliced form, HS6ST-2S, in humans and their different substrate specificities and restricted expression patterns in various tissues. We have also characterized human HS6ST-1 further and found a sharp difference in the expression pattern between humans and mice. Furthermore, we have examined the chromosomal localizations of genes for these enzymes for clues to the possibility that abnormal or defective expression of these genes may cause some diseases in humans. Overall, HS6STs could be important determinative factors for the tissue-and species-dependent differences in the fine structure of HS. , chondroitin sulphate A, chondroitin sulphate C, completely desulphated and N-resulphated heparin (CDSNS-heparin), 6-O-desulphated heparin (6ODS-heparin), 2-O-desulphated heparin (2ODS-heparin), HS from pig aorta and an unsaturated glycosaminoglycan (GAG) disaccharide kit were obtained from Seikagaku Corp. (Tokyo, Japan). Heparin from porcine intestinal mucosa, unlabelled adenosine 3h-phosphate 5h-phosphosulphate (PAPS), N-acetylglucosamine 6-sulphate and anti-FLAG M2 agarose were purchased from Sigma. Deacetylated and Nsulphated heparosan (NS-heparosan) was prepared by chemical deacetylation and N-sulphation from N-acetyl heparosan, which was prepared from Escherichia coli K5 by Dr Terumi Saito (Kanagawa University, Japan). [$&S]PAPS was prepared as described previously [37] .
EXPERIMENTAL Materials

Isolation of cDNAs encoding human HS6ST-2
Human counterparts to mouse HS6ST-2 were searched in DNA databases using the TBLASTN program. We found two cDNA genes (GenBank2 accession nos. AL049679 and AA315705) and two genomic DNAs (Z86064 and Z81365) covering the predicted coding region. The cDNA containing the whole coding region were amplified from the cDNA prepared from human brain RNA (ClonTech) by PCR using Q buffer (Qiagen, Valencia, CA, U.S.A.) and 5h-site primer (nt k14 to 6, CCAGCGTCGGGA-ACATGGAT ; 1 stands for the first nucleotide of the putative coding region) and 3h-site primer [nt 1507-1526, GCCATTTAA-CGCCATTTCTC]. The PCR products were purified and separated by 1 % (w\v) agarose-gel electrophoresis. These purified products were amplified again by pfu Taq polymerase (Stratagene) using 5h-primer with EcoRI site and 3h-primer with KpnI site. They were then digested with EcoRI and KpnI and cloned into EcoRI-KpnI site of pBluescript II KS.
A trial for molecular cloning of cDNAs encoding human HS6ST-3
Human counterparts of mouse HS6ST-3 were searched from the database using the TBLASTN program. We found two genomic DNAs (GenBank2 accession nos. AL158192 and AL138816) covering the predicted coding regions corresponding to exon 1 and exon 2 respectively. The two expected PCR fragments were amplified from human genomic DNA (ClonTech) using primer 1 (5h-site primer : nt 3-25, ACCATGGATGAAAGGTTCAACA-AGTGGC ; 1 implies the first nucleotide of putative coding region) and primer 2 (3h-site primer : nt 680-704, CTGGTGTG-GCTGTGGTTGCGGGGAC) and using primer 3 (5h-site primer : nt 705-732, GAATTTCTATTACATCACAATGTTA-CGG) and primer 4 (3h-site primer : nt 1392-1416, AGGTCAC-CATCTCACCACCTGGCTG) respectively. We then tried to amplify cDNAs from human brain RNA and human liver RNA (ClonTech) by reverse transcriptase (RT)-PCR using three sets of primers : 1 and 2, 3 and 4, and 1 and 4. The set of primers 3 and 4 yielded the cDNA, but the other sets have never brought about the amplification.
DNA sequence analysis
The subcloned cDNAs were sequenced on both strands by the dideoxy chain-termination method using Taq polymerase (dye terminator cycle sequencing ; PerkinElmer) with a DNA sequencer (Applied Biosystems PRISM 310, Foster, CA, U.S.A.). The DNA sequences thus obtained were compiled and analysed using GENETYX-MAX computer programs (Software Development Co., Tokyo, Japan). The nucleotide and deduced amino acid sequences were compared with other sequences in the nucleic acid and protein databases of GenBank2, DDBJ, dSTS and dbEST.
Construction of the expression vectors pFLAG-CMV2-hHS6ST-2, -2S and -1
For the construction of the expression vectors, pFLAG-CMV2-hHS6ST-2 and -2S, cDNA fragments containing open reading frames of 1497 bp for hHS6ST-2 and 1377 bp for hHS6ST-2S 6-O-sulphation of heparan sulphate were excised from pBluescript KS II with EcoRI and KpnI and ligated into the EcoRI-KpnI site of the pFLAG-CMV2 expression vector (Eastman Kodak Co., New Haven, CT, U.S.A.) respectively. The inserted sequences were confirmed on a single strand as described above. pFLAG-CMV2-hHS6ST-1 was constructed as described previously [26] .
Transfection of cDNAs and transient expression of HS6ST in COS-7 cells
COS-7 cells (5.5i10&) precultured for 48 h in a 60-mm culture dish were transfected with 5 µg of pFLAG-CMV2-hHS6ST-1, -2 and -2S respectively, or pFLAG-CMV2 alone. The transfection was performed using TransFast according to the manufacturer's recommended instructions (Promega, Madison, WI, U.S.A.). After incubation in Dulbecco's modified Eagle's medium containing 10 % (v\v) foetal calf serum and antibiotics for 72 h, the cell layers were washed with Dulbecco's modified Eagle's medium alone, scraped and homogenized in 1 ml of 10 mM Tris\HCl (pH 7.2), 0.5 % (w\v) Triton X-100, 0.15 M NaCl, 20 % (v\v) glycerol, 10 mM MgCl # and 2 mM CaCl # . The homogenates were subjected to stirring for 1 h and then centrifuged at 10 000 g for 30 min. FLAG fusion proteins in the supernatant (cell extract) were isolated by anti-FLAG M2 affinity chromatography according to the method described by the manufacturer, and the activities of HS6STs in the supernatants and FLAG-bound fractions were measured as described below.
Assay for sulphotransferase activities
Sulphotransferase activities were determined as described previously. Briefly, the standard reaction mixture (50 µl) contained 2.5 µmol of imidazole-HCl (pH 6.8), 3.75 µg of protamine chloride, 25 nmol (500 µM as hexosamine) of acceptor GAGs, 50 pmol of [$&S]PAPS (approx. 5i10& c.p.m. ; 1 µM) and enzyme. After incubation for 20 min at 37 mC, the reaction was stopped by heating at 100 mC for 1 min. Carrier chondroitin sulphate A (0.1 µmol as GlcA) was added to the reaction mixture, and the $&S-labelled polysaccharides were isolated by precipitation with ethanol containing 1.3 % (w\v) potassium acetate and 0.5 mM EDTA, followed by gel chromatography on a Fast Desalting column to remove [$&S]PAPS and its degradation products. The amounts of enzymes added to the reaction mixture were chosen so as to obtain a linear incorporation of [$&S]sulphate. We measured $&S incorporation into various GAGs with each purified recombinant enzyme under the conditions. One unit of enzyme activity was defined as the amount required to transfer 1 pmol of sulphate\min to CDSNS-heparin.
Measurement of the relative specific activity of FLAG-tagged recombinant human HS6ST-2 and HS6ST-2S proteins
The FLAG fusion proteins were purified as described above. The relative amounts of the FLAG-tagged proteins were determined by Western blotting using anti-FLAG antibody. Immune complexes were detected using the ECL2 detection system (Amersham Pharmacia Biotech) and the density of the protein bands were quantified by NIH image software (version 1.57).
Analysis of enzymic reaction products
Analysis of the reaction products was performed by HPLC as described previously [38] with some modifications. Briefly, $&S-labelled products were digested with a mixture of 10 m-units of heparitinase I, 5 m-units of heparitinase II and 10 m-units of heparitinase III in 40 µl of 50 mM Tris\HCl (pH 7.2), 1 mM CaCl # and 4 µg of BSA at 37 mC for 2 h. The digests were subjected to gel chromatography on Superdex 30 pg equilibrated with 0.2 M NH % HCO $ . The $&S-labelled disaccharide fractions were injected on to a PAMN column together with standard unsaturated disaccharides. Fractions of 0.6 ml were collected and their radioactivities were measured. Unsaturated hexuronic acid (HexA) residues of the unsaturated disaccharides were cleaved by treatment with mercuric acetate [39, 40] . Unsaturated disaccharide fraction (100 µl) was added to 100 µl of 70 mM mercuric acetate adjusted to pH 5.0 and the mixture was left at room temperature (25 mC) for 30 min. To remove mercuric acetate, 60 µl of a 50% slurry of Dowex 50 H + resin was added to the reaction mixture and then the resin was removed by filtration. The resin was washed with water. The pass-through fractions and wash fractions were combined, neutralized with 2 M NaOH and then subjected to PAMN column chromatography.
Northern-blot analysis
Human multiple tissue Northern-blot filters, on which 2 µg of polyadenylated RNAs from various human tissues were blotted, were prehybridized in ExpressHyb Hybridization Solution TM (ClonTech) at 68 mC for 30 min and then hybridized in the same solution containing $#P-labelled probes (1i10' c.p.m.\ml) at 68 mC for 1 h. The probes used were a 1203-base fragment at positions 280-1482 of the hHS6ST-1 cDNA (probe 1), a 1377-base fragment at the coding region of the hHS6ST-2S cDNA (probe 2, cross-hybridization for both hHS6ST-2cDNA and hHS6ST-2ScDNA) and a 120-base fragment at positions 510-629 of the hHS6ST-2 cDNA (probe 3, specific hybridization for hHS6ST-2) respectively. Probes 1 and 2 were labelled with [α-$#P]dCTP by random oligonucleotide priming (Ready-to-Go DNA labelling kit ; Amersham Pharmacia Biotech). Probe 3 was labelled at the 5h-end with [γ-$#P]ATP using T4 polynucleotide kinase. The membranes were washed several times with 2iSSC and 0.05 % SDS at room temperature and subsequently with 0.1iSSC and 0.1 % SDS at 50 mC twice. The membranes were exposed to X-ray film with an intensifying screen at k80 mC.
Chromosome preparation and in situ hybridization
The direct R-banding fluorescence in situ hybridization (FISH) method was used for the chromosomal assignment of the human HS6ST-1 and human HS6ST-2 genes. The preparation of Rbanded chromosomes and FISH were performed as described by Matsuda et al. [41] . The 2.0 and 1.5 kb human cDNA fragments inserted in the EcoRI site of pBluescript were used for chromosomal mapping of HS6ST-1 and HS6ST-2 genes respectively. The cDNAs were labelled by nick translation with biotinylated 16-dUTP (Roche Diagnostics, Branchburg, NJ, U.S.A.) following the standard procedures. The hybridized biotinylated probes were reacted with goat anti-biotin antibodies (Vector Laboratories, Burlingame, CA, U.S.A.), and then stained with fluoresceinated anti-goat IgG (Nordic Immunology, Oslo, Norway). FISH images were observed under Nikon fluorescence microscope using Nikon filter sets B-2A and UV-2A. Kodak Ektachrome ASA100 films were used for microphotography.
RESULTS
Molecular cloning of human isologues of mouse HS6STs and the occurrence of HS6ST-2S, alternative spliced form of HS6ST-2 in human
We cloned human HS6ST-1 previously and characterized this enzyme [26] . In the present study, we aimed to investigate human
Figure 1 RT-PCR amplifications of two forms of human HS6ST-2
The cDNA prepared from human brain RNA was amplified using a 5h-site primer (nt k14 to 6, CCAGCGTCGGGAACATGGAT ; 1 stands for the first nucleotide of putative coding region) and 3h-site primer (nt 1507-1526, GCCATTTAACGCCATTTCTC). The PCR products were subjected to 1 % agarose-gel electrophoresis.
counterparts to the other two isoforms of mouse HS6ST. For cloning HS6ST-2, we searched DNA databases using the TBLASTN program, and found two cDNA genes (GenBank2 accession nos AL049679 and AA315705) and two genomic DNAs (Z86064 and Z81365) covering the predicted coding region. The cDNA prepared from human brain RNA was amplified using 5h-and 3h-site primers as described in the Experimental section. Agarose-gel electrophoresis of the PCR products revealed two bands ( Figure 1) ; the size of one band was 1500 bp that was a length expected from mHS6ST-2, and the size of another band was approx. 1400 bp. The predicted amino acid sequence deduced from the nucleotide sequences of the longer PCR product showed 92 % identity with the sequence of mHS6ST-2, and also indicated the presence of one hydrophobic segment in the N-terminal region and nine putative N-glycosylation sites as observed in mHS6ST-2 ( Figure 2 ). On the other hand, the nucleotide sequence of the shorter PCR product was identical with the sequence of hHS6ST-2, except for the loss of 120 bases that resulted in the deletion of 40 amino acids from position 171-210 in hHS6ST-2 (enclosed by a box in Figure 2 ). Since the protein deduced from the shorter PCR product still had two consensus sequences for PAPS-binding sites, a 5h-phosphosulphate-binding (5h-PSB) site and a 3h-phosphate-binding (3h-PB) site (Figure 2) , it was expected to have sulphotransferase activity. Therefore we named this novel form as hHS6ST-2S. A genome analysis using Z81365 and Z86064 showed that the human HS6ST-2 gene consists of four exons and spans more than 156 kb from the first ATG to the poly (A) signal. Also the mHS6ST-2 genome comprises four exons (H. Habuchi and K. Kimata, unpublished work). Comparison of the nucleotide sequences of hHS6ST-2S with those of Z81365 and Z86064 revealed that hHS6ST-2S was a spliced form lacking exons 2 and 3 ( Figure 3 ). To examine if other spliced variants lacking either exon 2 or 3 may occur, we performed the second PCR using the cDNA products from human brain RNA by RT-PCR as template and a set of primers (the forward primer, nt 382-406 and the reverse primer, nt 710-734). Only two DNA bands of approx. 330 and 210 bp were detected, which were assigned to the products from hHS6ST-2 and from hHS6ST-2S respectively. None of the DNA bands for the other spliced variants lacking either exon 2 or 3 were detected. The results suggested that the other hypothetical spliced variants are not expressed, at least in the brain. For cloning the human isologue of mHS6ST-3, we also searched DNA databases and found two genomic DNAs covering this region. However, several attempts to isolate the complete cDNA using brain and liver cDNA libraries did not succeed, although the 3h-site of the predicted coding region, nucleotides 705-1416, was amplified. The failure in the amplification may be caused by the presence of differently spliced forms, because Northern-blot analysis of mHS6ST-3 revealed the presence of many spliced forms [27] .
Expression of hHS6ST-2 and hHS6ST-2S cDNAs in COS-7 cells and enzyme properties of the expressed proteins of human HS6STs
The cDNAs were inserted into a mammalian expression vector, pFLAG-CMV2, and COS-7 cells were transfected with either pFLAG-CMV2-hHS6ST-2 or pFLAG-CMV2-hHS6ST-2S, or with the vector alone as a control. Sulphotransferase activity in the cell extracts from these transfected cells was assayed using CDSNS-heparin as a substrate. The total activity of sulphotransferases in the cells transfected with pFLAG-CMV2-hHS6ST-2 and with pFLAG-CMV2-hHS6ST-2S was increased approx. 12-and 7-fold respectively, over the control (results not shown), suggesting that both the isolated cDNAs encoded proteins having HS6ST activity. The activity of sulphotransferase in the transfectants with pFLAG-CMV2-hHS6ST-1 was also increased as reported previously [26] . The recombinant enzymes were purified by anti-FLAG monoclonal antibody affinity chromatography and the relative amounts of the purified proteins were estimated by measuring the staining intensities of the FLAG-tag bands using anti-FLAG antibody as described in the Experimental section. The relative specific activities of those recombinant hHS6STs were almost equal to each other (results not shown). Their sulphotransferase activities were examined towards various heparin derivatives, HSs from different sources or other GAGs at a concentration of 500 µM (as hexosamine) ( Table 1 ). The differences in substrate structure among the heparin derivatives and HS samples were characterized by disaccharide composition analysis ( Table 2 ). All enzyme proteins tested were able to transfer sulphate to CDSNS-heparin, 6ODS-heparin, NS-heparosan, heparin and HS preparations ; the activity towards heparin was relatively low. We then examined the effects of concentration of CDSNS-heparin, NS-heparosan and HS on the activity of these enzymes to characterize substrate specificities of hHS6ST-2, -2S and hHS6ST-1 (Figure 4) . The activities of the recombinant hHS6ST-2, hHS6ST-2S and hHS6ST-1 towards NS-heparosan and HS were increased with the increasing concentrations of the substrates. The activity of hHS6ST-1 towards CDSNS-heparin also increased with the increasing concentration, whereas those of hHS6ST-2 and hHS6ST-2S towards CDSNC-heparin, on the other hand, showed a maximum at 100 µM and decreased at the higher concentrations, indicating that the substrate preference of hHS6ST-2 appeared to be similar to that of hHS6ST-2S, but not to hHS6ST-1. Such concentration-dependent differences in sub-6-O-sulphation of heparan sulphate
Figure 2 Nucleotide sequences of the human HS6ST-2 and -2S cDNA, and the predicted amino acid sequences
The predicted amino acid sequence is shown below the nucleotide sequence. The putative transmembrane hydrophobic domain is underlined. Potential N-linked glycosylation sites are shown by black dots. The deleted portion in human HS6ST-2S is shown within a box. The putative PAPS-binding sites are shown by white box for 5h-phosphosulphate and black boxes for 3h-phosphate in PAPS.
strate preferences between hHS6ST-1 and hHS6ST-2 appeared to be similar to those between corresponding mouse isologues reported previously [28] .
The mechanism for the decreasing activities of hHS6ST-2 and hHS6ST-2S at the higher concentrations of CDSNS-heparin is not clear at the moment. However, we found that 2ODS-heparin, which has a structure corresponding to the products from CDSNS-heparin by hHS6ST-2 and hHS6ST-2S, strongly inhibited both the hHS6ST-2 and hHS6ST-2S activities (results not shown), suggesting that the two forms of hHS6ST-2 may have products that lead to inhibition of the enzyme reaction (so-called product inhibition). As shown in Table 2 , 1.4 % of GlcNSO $ units in CDSNS-heparin used for the acceptor substrate still harbour 6-O-sulphate residue. Therefore the observed biphasic concentration dependency of their activities when CDSNS-heparin was used as acceptor substrate could be due to both these enzyme properties and the contaminating products in the substrate. However, the decrease in the activity of hHS6ST-2 and hHS6ST-2S was not observed when NS-heparosan and HS (pig aorta) were used as the acceptors. Therefore one may consider that high IdoA content of CDSNS-heparin may also contribute to its inhibitory activity.
Analysis of sulphation sites of acceptor substrates
We examined the sulphation positions of the acceptor substrates by analysing the structures of the $&S-labelled products obtained from HS (pig aorta) or CDSNS-heparin on incubation with each recombinant enzyme and [$&S]PAPS. The $&S-labelled products were digested with a mixture of heparitinases I, II and III, and 
Table 1 Acceptor substrate specificities of the recombinant sulphotransferases purified by anti-FLAG antibody affinity column chromatography
Sulphotransferase activities were assayed using various glycosaminoglycans (500 µM) as acceptors. Sulphotransferase fractions were prepared from COS-7 cells transfected with pFLAG-CMV2-hHS6ST-1, pFLAG-CMV2-hHS6ST-2 and pFLAG-CMV2-hHS6ST-2S respectively, as described in the Experimental section. Recombinant proteins were purified on the anti-FLAG antibody column. 
Table 2 Disaccharide compositions of heparin, modified heparin, N-sulphated heparosan and HSs used as substrates
The unsaturated disaccharide compositions of various glycosaminoglycans are expressed as percentages of total disaccharides.
Glycosaminoglycans Unsaturated disaccharides (% of total)
∆Di-OS ∆Di-6S ∆Di-NS ∆Di-(N,6)diS ∆Di-(N,2)diS ∆Di-(N,6,2)triS 
Figure 4 Effects of variable concentrations of acceptor substrates on the activities of hHS6ST-2 (A), hHS6ST-2S (B) and hHS6ST-1 (C)
The sulphotransferase activity was measured using 0.4 unit of recombinant enzyme as described in the Experimental section, except that various amounts of CDSNS-heparin ($), NSheparosan (#) or HS (pig aorta) () were added. Values represent means of triplicate independent experiments.
then subjected to gel chromatography on Superdex 30 pg and subsequently to PAMN column chromatography. More than 95 % of the digests of the $&S-labelled products from CDSNSheparin after incubation with each recombinant enzyme were eluted in the disaccharide fractions from the Superdex 30 column, 6-O-sulphation of heparan sulphate
Figure 5 Superdex 30 pg chromatography of the heparitinase digests of 35 S-labelled products derived from HS (pig aorta) by incubation with [ 35 S]PAPS and with the recombinant purified hHS6ST-2 (A), hHS6ST-2S (B) and hHS6ST-1 (C)
The recombinant purified enzymes were prepared as described in the Experimental section. and most of the radioactivity in the disaccharide fractions was eluted at the position of 2-deoxy-2-sulphamino-4-O-(4-deoxy-α--threo-hex-4-enepyranosyluronic acid)-6-O-sulpho--glucose [∆Di-(N,6)diS] by the subsequent PAMN column chromatography (results not shown). In contrast, the digests of the $&S-labelled products from HS (pig aorta), when applied to Superdex 30 pg column, were eluted in the tetrasaccharide fractions (molecular mass was approx. 950 Da) as well as in the disaccharide fractions, and both the elution profiles of the disaccharide fractions and the proportions of tetrasaccharide to disaccharide fractions were very different among the three recombinant enzymes ( Figure 5 ). The subsequent PAMN
Figure 6 HPLC on PAMN columns of the disaccharide fractions obtained by heparitinase digestion of 35 S-labelled products derived from HS (pig aorta) by incubation with [ 35 S]PAPS and with the recombinant purified hHS6ST-2 (A), hHS6ST-2S (B) and hHS6ST-1 (C)
The disaccharide fractions indicated by horizontal bars in Figure 5 were subjected to PAMN column chromatography as described in the Experimental section. The elution was carried out with a linear gradient of 40-550 mM KH 2 PO 4 for 40 min and then at 550 mM KH 2 PO 4 for 10 min. The dotted lines indicate concentrations of KH 2 PO 4 used for the elution. The closed circles show the elution patterns of the products derived from HS (pig aorta). The fractions indicated by horizontal bars were collected and desalted by Superdex 30 pg gel chromatography and freeze-dried. These samples were used for the next step. The arrows indicate the elution positions of ∆Di-
column chromatography of the disaccharide fractions (indicated by horizontal bars in Figure 5 ) showed an elution profile consisting of three peaks corresponding to ∆Di-(N,6)diS, 2-deoxy-2-sulphamino-4-O-(4-deoxy-2-O-sulpho-α--threo-hex-4-enepyranosyluronic acid)-6-O-sulpho--glucose [∆Di-(N,6,2) triS] and an unidentified compound (peaks 3, 5 and X in Figure  6 respectively). Since peak X eluted between 2-acetamido-2-deoxy-4-O-(4-deoxy-α--threo-hex-4-enepyranosyluronic acid)-6-O-sulpho--glucose (∆Di-6S) and 2-deoxy-2-sulphamino-4-O-(4-deoxy-α--threo-hex-4-enepyranosyluronic acid)--glucose (∆Di-NS) from the PAMN column (Figure 6 ), and near 2-acetamido-2-deoxy-4-O-(4-deoxy-α--threo-hex-4-enepyranosyl-
Figure 7 HPLC on PAMN columns of 35 S-labelled peak X (A) and ∆Di-(N,6)diS (B) treated with mercuric acetate
The peak X fraction and ∆Di-(N,6)diS fraction in Figure 6 (C) were collected and treated with mercuric acetate as described in the Experimental section. The reaction products were chromatographed again on the PAMN column. The elution was carried out with a linear gradient of 10-540 mM KH 2 PO 4 for 40 min. The eluate was monitored by measuring the absorbance at 215 nm. The arrows in (A) indicate the elution positions of the internal standards : ∆Di-OS (I), GlcNAc-6SO 4 (II), ∆Di-6S (III), ∆Di-NS (IV), ∆Di-(N,6)diS (V) and ∆Di-(N,2)diS (VI).
uronic acid)--glucose (∆Di-OS) on Superdex 30 gel chromatography (results not shown), and, in addition, a disulphated monosaccharide, N-sulphoglucosamine 6-sulphate [GlcNSO $ (6SO % )], had been found to be released from the non-reducing end of HS after the heparitinase II digestion [42] , we assumed peak X to be a sulphated monosaccharide. To confirm that peak X corresponded to GlcNSO $ (6SO % ), $&S-labelled peak X and $&S-labelled ∆Di-(N,6)diS were treated with mercuric acetate to remove unsaturated HexA residues [39, 40] , and the reaction products were again chromatographed on the PAMN column ( Figure 7) . Most of the radioactivity of the treated peak X was recovered at the position of the starting materials ( Figure 7A ), whereas the radioactivity of the reaction product from ∆Di-(N,6)diS, which was expected to be GlcNSO $ (6SO % ), was eluted at the same position as peak X ( Figure 7B ). Furthermore, considering that GlcNAc(6SO % ) is eluted at peak 2 (13.2 min) by PAMN column chromatography, peak X probably corresponds to GlcNSO $ (6SO % ). Percentages of the $&S radioactivity incorporated into GlcNSO $ (6SO % ), ∆Di-(N,6)diS and ∆Di-(N,6,2)triS are shown in Figure 8(A) . The disaccharide fractions of the $&S-labelled products from 6ODS-heparin were likewise analysed. The major products were GlcNSO $ (6SO % ), ∆Di-(N,6)diS and ∆Di-(N,6,2)triS, and their percentages of $&S radioactivity are shown in Figure 8(B) . There was a considerable difference in the relative incorporation into the major three products not only between the two substrates but also among the three enzymes. For GlcNSO $ (6SO % ) derived from the non-reducing end, the value was 24 % from pig aorta HS and below 4 % from 6ODS- Figure 8 The ratio of GlcNS6S, ∆Di-(N,6)diS and ∆D-(N,6,2)triS derived from heparitinase digestion of 35 
S-labelled products derived from pig aorta HS (A) and 6ODS-heparin (B)
The percentages of 35 heparin, and the relative incorporation into ∆Di-(N,6)diS and ∆Di-(N,6,2)triS derived from internal GlcNSO $ residues in HS was quite different among the three enzymes. The tetrasaccharide fractions from the Superdex 30 column may contain 3-Osulphated residues or receive further modifications, as judged from the reported heparitinase substrate specificities [43] , but it was difficult to determine the structures at the radioisotope level. Considering the results together, hHS6ST-2 appeared to have a preference to transfer sulphate to position 6 of GlcNSO $ residues in IdoA 2-O-sulphate [IdoA(2SO % )-GlcNSO $ ] unit or highly sulphated regions, and hHS6ST-1 to transfer sulphate to position 6 of GlcNSO $ residues in HexA-GlcNSO $ unit. Interestingly, hHS6ST-2S had a preference that was somewhere in between. These preferences were clearer in pig aorta HS.
Expression of transcripts in various tissues
The tissue-dependent expression was compared among the two forms of HS6ST-2 and HS6ST-1 by dot-blot analysis using the Human Multiple Tissue Expression (MTE TM ) Array (Figure 9 ; ClonTech). When probe 3 was used for the detection of the original form of hHS6ST-2 ( Figure 9A ), positive signals were only detected in tissues related to brain, particularly in the thalamus, putamen, occipital lobe, amygdala and caudate nucleus. On the other hand, when probe 2, which is capable of hybridizing both hHS6ST-2 and hHS6ST-2S was used, positive signals were observed in ovary, foetal kidney, placenta and 6-O-sulphation of heparan sulphate
Figure 9 Dot-blot analysis of hHS6ST-2 (A), hHS6ST-2 and hHS6ST-2S (B) and hHS6ST-1 (C) transcripts in various human tissues
The sources of the polyadenylated [poly(A) + ] RNA are indicated in (D). The same membrane was hybridized sequentially with 32 P-labelled probes 1, 2 and 3 respectively, as described in the Experimental section.
kidney in addition to the tissues detected with probe 3 ( Figure  9B ), which suggested that the short form (hHS6ST-2S) was expressed mainly in ovary, placenta and foetal kidney. hHS6ST-1 was expressed rather ubiquitously in various tissues, although a higher level of expression was observed in adrenal gland, kidney, liver, intestine, foetal brain and foetal kidney ( Figure  9C ).
Assignment of the human HS6ST-1 and HS6ST-2 genes by FISH
Human HS6ST-1 and HS6ST-2 genes are found at chromosome (Chr) 2q21 and Xq25 respectively, in the DNA database. To investigate more closely the loci of these genes to know if they are related to human diseases, we applied the directed R-banding FISH as described in the Experimental section. HS6ST-1 and HS6ST-2 were localized to Chr 2q21.1 and Chr Xq26.1 respectively (ISCN, 1985 ; Figure 10) . Interestingly, the genes for glypicans 3 and 4, which are glycosylphosphatidylinositol-anchored cell-surface HSPGs, are on chromosome Xq26.1, close to the hHS6ST-2 gene.
DISCUSSION
In this study, we have investigated the human counterparts of mouse HS6ST isoforms, which we reported previously [27] , and found that human HS6ST-2 is present in two forms : the original long form (hHS6ST-2) and a short form (hHS6ST-2S). The latter was generated by alternative splicing in the coding region of the HS6ST-2 gene, and lacked 40 amino acids encoded by exons 2 and 3. In spite of this deletion, HS6ST-2S still had two PAPSbinding sites which are present in exons 1 and 4 respectively. It catalysed the transfer of sulphate from PAPS to position 6 of the GlcNSO $ residue in HS, and its specific activity was not significantly different from that of HS6ST-2. The activity profiles of hHS6ST-2 and hHS6ST-2S towards various substrates were somewhat similar to each other, but quite different from those of hHS6ST-1 (Table 1) . Structural analysis of the $&S-labelled products formed from HSs with the recombinant enzymes also suggested a difference in the way hHS6ST-2 showed a preference to transfer sulphate to position 6 of GlcNSO $ residues in IdoA(2SO % )-GlcNSO $ unit or highly sulphated regions, whereas hHS6ST-1 transferred sulphate to position 6 of GlcNSO $ residues in HexA-GlcNSO $ unit. Detailed analysis for the structures of the $&S-labelled products formed from HSs revealed that hHS6ST-1, hHS6ST-2 and hHS6ST-2S were all capable of transfering sulphate not only to position 6 of internal GlcNSO $ residue of the HS as described above, but also to position 6 of GlcNSO $ residues at the nonreducing end of the acceptor substrates. One may wonder here if GlcNSO $ (6SO % ) could be formed from the unsaturated disaccharides during the digestion with heparitinases, due to the possible contamination of β-glycuronidase acting on unsaturated uronic acid or chemical instability. However, this is unlikely, because little GlcNSO $ (6SO % ) monosaccharide was detected in the digests of the $&S-labelled products from CDSNS-heparin, in which ∆Di-(N,6)diS was a major component. As observed with GalNAc4S-6ST (where GalNAc stands for N-acetylgalactosamine) purified from squid cartilage, which catalysed the 6-sulphation of both the internal and non-reducing terminal GalNAc4SO % residues of chondroitin sulphate [44, 45] , it is probable that all of these HS6STs can transfer sulphate to position 6 of GlcNSO $ residues located not only in the internal repeating units, but also at the non-reducing end in HS. GlcNSO $ (6SO % ) may actually be present at the non-reducing end of native HS, because a previous study [42] described that digestion of HS from the lung and pancreas with heparitinase II yielded the release of 5 and 4 % GlcNSO $ (6SO % ) monosaccharide relative to the total product respectively. Recently, it has been suggested that a GlcNAc-6-sulphatase secreted into the extracellular space contributes to the regulation of HS-dependent Wnt signalling by the modification of the structure of HS [46] . Based on the homology in amino acid sequence between the extracellular GlcNAc-6-sulphatase and the lysosomal GlcNAc-6-sulphatase that hydrolyses 6-O-sulphate on the non-reducing terminal GlcNAc and GlcNSO $ [47] , the extracellular GlcNAc-6-sulphatase could cleave 6-O-sulphate at the non-reducing terminal GlcNAc and GlcNSO $ . If this is the case, it may be that sulphation and desulphation of the GlcNSO $ (6SO % ) residues located at the non-reducing end of HS modify the binding of Wnt to HS.
We detected only a trace of activity to transfer sulphate to position 6 of GlcNAc residues in HS with the recombinant hHS6ST-1, hHS6ST-2 or hHS6ST-2S under the reaction conditions used in the present study, although HSs are rich in GlcNAc residues. In contrast with these results, Chinese-hamster ovary (CHO) cell transfectants that were overexpressing mHS6ST-1 or mHS6ST-2 or mHS6ST-3 produced HS containing much more HexA-GlcNAc(6SO % ) when compared with wild-type CHO-K1 cells (H. Habuchi and K. Kimata, unpublished work). Zhang et al. [48] also have reported that CHO cells transfected with HS6ST-1 generated HS containing more HexA-GlcNAc(6SO % ) than the original cells. They claimed that HS6ST-1 could sulphate GlcNAc residues in AT III-binding sites in itro [48] . Considering our observations on the weak activity of the recombinant HS6STs towards GlcNAc residues in itro, the following explanations are equally possible : (1) the acceptor substrates used in the present study do not contain structural domains required for the sulphation of position 6 of GlcNAc residues ; (2) there are Golgilocalized factors that stimulate the 6-O-sulphation of GlcNAc in the cell ; and (3) as other GlcNAc 6-O-sulphotransferases transfer 6-O-sulphation of heparan sulphate sulphate to position 6 of terminal GlcNAc residues in keratan sulphate and oligosaccharides [17] , in i o 6-O-sulphation of GlcNAc residues in HS may be performed in a similar way, i.e. the sulphation could take place when the chain is elongating.
Dot-blot analysis showed that each HS6ST isoform has its own characteristic pattern of expression. The original hHS6ST-2 was expressed characteristically in brain-related tissues. It is intriguing that alternative splicing of hHS6ST-2 strictly occurred in a tissue-dependent manner. Comparison in the expression pattern between Figures 9(A) and 9(B) revealed that the short form (hHS6ST-2S) was preferentially expressed in ovary, placenta and foetal kidney. Human HS6ST-1 was expressed rather constitutively in various tissues in sharp contrast with our previous findings that mouse HS6ST-1 was expressed preferentially in liver [27] . The observations suggest that isologues of HS6STs have similar enzymic properties but differ in their expression in certain tissues, depending on the animal species, and may be partly responsible for some of the species-specific tissue functions.
We have mapped more precisely the HS6ST-2 gene to Xq26.1 and the HS6ST-1 gene to 2q21.1 respectively, using directed Rbanding FISH. We then examined any inherited disorders related to these chromosomal sites using the Online Mendelian Inheritance-in-Man database. No such disease was mapped to 2q21.1 where HS6ST-1 is localized, whereas several diseases were mapped to Xq26 where HS6ST-2 was localized. The genes responsible for some of these diseases have already been identified, but the genes responsible for premature ovarian failure, Charcot-Marie-tooth disease and Panhypropituitarism disease have not. It is uncertain at this stage whether or not the HS6ST-2 gene is related to any of these disorders.
Our preliminary results have suggested that the short form of HS6ST-2 is also expressed in mice. In addition, we have detected this form in chicken. However, interestingly, to the best of our knowledge, the long form has not been detected (K. Nogami, H. Suzuki, H. Habuchi, H. Iwata and K. Kimata, unpublished work), suggesting that the short form is in fact the original from an evolutionary perspective. Considering that no isoform for HS6ST was detected in Drosophila [32] , it is interesting to speculate that higher animals with more isoforms may have the capacity to create a more diverse and finer structure for HS, which could reflect more functional diversity.
As observed in mouse HS6ST, both the expressed proteins from human HS6ST-2 and HS6ST-2S cDNA were secreted into the culture medium. The secretion of HS6ST seems to occur under physiological conditions, because the HS6ST activity was detected in human serum. However, at this time it remains to be studied how the secreted HS6STs differ in function from those present inside the cells and whether one or both of the isoforms of HS6ST are present in serum. Several heparin-binding cell growth factors such as vascular endothelial growth factor and fibroblast growth factor 2 are involved in the angiogenesis that often takes place in malignant tumour tissues [49] . It is now known that HSPGs, especially 6-O-sulphated HSPGs, play essential roles in signalling [33] [34] [35] . The determination of HS6ST activities in sera from patients with different tumours will provide information on the correlation between these activities and disease.
